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Abstract
Androgens are important regulators of bone mass but the relative importance of testosterone (T) versus
dihydrotestosterone (DHT) for the activation of the androgen receptor (AR) in bone is unknown. 5a-reductase is
responsible for the irreversible conversion of T to the more potent AR activator DHT. There are two well established
isoenzymes of 5a-reductase (type 1 and type 2), encoded by separate genes (Srd5a1 and Srd5a2). 5a-reductase type 2 is
predominantly expressed in male reproductive tissues whereas 5a-reductase type 1 is highly expressed in liver and
moderately expressed in several other tissues including bone. The aim of the present study was to investigate the role of 5a-
reductase type 1 for bone mass using Srd5a1
2/2 mice. Four-month-old male Srd5a1
2/2 mice had reduced trabecular bone
mineral density (236%, p,0.05) and cortical bone mineral content (215%, p,0.05) but unchanged serum androgen levels
compared with wild type (WT) mice. The cortical bone dimensions were reduced in the male Srd5a1
2/2 mice as a result of a
reduced cortical periosteal circumference compared with WT mice. T treatment increased the cortical periosteal
circumference (p,0.05) in orchidectomized WT mice but not in orchidectomized Srd5a1
2/2 mice. Male Srd5a1
2/2 mice
demonstrated a reduced forelimb muscle grip strength compared with WT mice (p,0.05). Female Srd5a1
2/2 mice had
slightly increased cortical bone mass associated with elevated circulating levels of androgens. In conclusion, 5a-reductase
type 1 inactivated male mice have reduced bone mass and forelimb muscle grip strength and we propose that these effects
are due to lack of 5a-reductase type 1 expression in bone and muscle. In contrast, the increased cortical bone mass in
female Srd5a1
2/2 mice, is an indirect effect mediated by elevated circulating androgen levels.
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Introduction
Androgens are of major importance for bone growth and
maintenance [1–3]. The effects of testosterone (T) can be exerted
either directly through the androgen receptor (AR) or indirectly
through aromatization to estrogens, exerting their effects through
estrogen receptors (ERa and/or ERb [1,2]). All these receptors are
expressed both in growth plate cartilage and in bone [4–8]. Both
ERa-activation and AR-activation but not ERb-activation are
required for a normal bone mass and bone health in males [9–14].
5a-reductase enzymes are responsible for the irreversible conver-
sion of T to the more potent AR activator DHT. We have
previously reported that DHT treatment increases bone mass in
orchidectomized mice and that this effect is independent of
estrogen receptors [11]. The relative importance of endogenous T
versus DHT for the activation of the AR in bone is unknown.
The DHT-AR complex has a longer half-life and a higher DNA
binding affinity than the T-AR complex. Therefore, the effective
dose of DHT, required to activate an androgen responsive marker
gene by 50%, is about 10-fold lower than that required to achieve
the same level of induction with T [15–19]. It is proposed that the
conversion of T to DHT by tissue specific 5a-reductase activity
results in a tissue specific signal amplification of the androgenic
activity [20].
There are two well established isoenzymes of 5a-reductase (type
1 and type 2), encoded by separate genes (Srd5a1 and Srd5a2;
[21–25]). In addition, it has recently been proposed by Uemeura et
al that a third 5a-reductase enzyme, type 3 encoded by Srd5a3, has
the capacity to produce DHT from T [25]. However, others claim
that 5a-reductase type 3 has little or no functional ability to reduce
steroid substrates but rather has a crucial role in N-linked protein
glycosylation [21,24].
Both 5a-reductase type 1 and type 2 clearly have the capacity to
convert T to DHT but they have different tissue distribution and
enzymatic activities. 5a-reductase enzymes have the capacity to
catalyse not only anabolic but also catabolic reactions in the
androgen metabolism [26]. Thus, conversion of T into DHT also
marks the latter hormone for degradation to the inactive
compound 3a-Adiol [27]. The biochemical properties and tissue
distribution of the type 1 isoenzyme are those of a catabolic agent,
with a low affinity for steroid substrates and a high expression in
the liver. In contrast, a high substrate affinity and a predominant
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21402expression in male reproductive tissues indicate that the type 2
isoenzyme is an anabolic entity [26]. However, 5a-reductase type
1 is not only expressed in the liver but also in several peripheral
tissues including bone and cartilage, suggesting that it might be
involved in signal amplification of the androgenic activity in the
skeleton [28–30].
There are no reported cases of 5a-reductase type 1 deficiency in
humans. Female Srd5a1
2/2 mice exhibit a parturition defect due
to impaired cervical ripening caused by a defected local catabolism
of progesterone [31], while male mice have an apparent normal
reproductive phenotype [27].
Since 5a-reductase type 1 is expressed in bone and has the
capacity to amplify the androgenic signal, we hypothesized that
5a-reductase type 1 mediated local conversion of T to the more
potent androgen DHT might be of importance for bone
metabolism. We, therefore, analyzed the skeletal phenotype of
Srd5a1
2/2 mice.
Results
Tissue distribution of 5a-reductase isoforms
The mRNA levels of the two well established 5a-reductase
isoforms, type 1 and type 2, were analyzed in several tissues from
adult wild type (WT) mice. The highest mRNA levels of 5a-
reductase type 1 were found in liver, while the highest levels of 5a-
reductase type 2 were found in male reproductive tissues
(epididymis and prostate; Fig. 1). The type 1 mRNA levels were
>100-fold while the type 2 mRNA levels were as much as
>50.000-fold lower in bone compared with the tissue with the
highest expression of the respective 5a-reductase isoform (Fig. 1).
In addition, we analyzed the tissue distribution of the proposed,
but less established, 5a-reductase type 3 enzyme, demonstrating
the highest mRNA levels in male reproductive tissues and >10-
fold lower mRNA levels in liver and bone (Fig. 1). The general
tissue distribution of the three 5a-reductase isoforms in non-
reproductive tissues did not differ between male and female mice.
Body weight and visceral organs in Srd5a1
2/2 mice
There was no significant difference in body weight, crown-rump
length or tibia length between Srd5a1
2/2 and WT mice (Table 1).
Furthermore, Srd5a1
2/2 mice displayed normal weights of
seminal vesicles, uterus and gonadal fat. Female but not male
Srd5a1
2/2 mice had reduced thymus weight compared with WT
mice (Table 1).
Reduced areal BMD and BMC in Srd5a1
2/2 mice
Dual energy X-ray absorptiometry (DXA) measurements of
tibia demonstrated that the areal BMD (28.9%, p,0.05) and the
BMC (217.8%, p,0.01) were reduced in four-month-old male
Srd5a1
2/2 mice compared with male WT mice (Fig. 2). Neither
areal BMD nor BMC was significantly affected in female Srd5a1
2/
2 mice compared to female WT mice.
Reduced trabecular BMD and cortical BMC in male, but
increased cortical BMC in female Srd5a1
2/2 mice
As the DXA technique cannot distinguish between the cortical
and trabecular bone compartments, detailed analyses using pQCT
were performed to further characterize the bone phenotype in
Srd5a1
2/2 mice. The trabecular BMD was reduced (236%,
p,0.05) in male Srd5a1
2/2 mice compared with WT mice while it
was not significantly affected in female Srd5a1
2/2 mice (Fig. 3).
Cortical bone parameters were determined with mid-diaphyseal
pQCT scans of the long bones. The cortical bone mineral content
(BMC) was decreased in male (214.6%, p,0.05) but slightly
increased in female (+9.1%, p,0.05) Srd5a1
2/2 mice compared
with WT mice (Fig. 4A). The reduced cortical BMC in male
Srd5a1
2/2 mice was due to a reduced cortical bone area (213.9%;
p,0.05) while the cortical BMD was unaffected compared with
WT mice (Fig. 4B and Table 2). The cortical bone area, in turn,
was reduced as a result of reduced periosteal circumference
(Fig. 4C; 29.8%, p,0.05). Consequently, male Srd5a1
2/2 mice
displayed a reduction of cortical bone parameters reflecting bone
strength, including cortical cross-sectional moment of inertia and
cortical moment of resistance (p,0.05; Table 2). The increased
cortical BMC in female Srd5a1
2/2 mice was due to an increased
cortical bone area (+7.9%; p,0.05) associated with an increased
cortical thickness (+9.6%; p,0.05; Fig. 4B, Table 2).
As expected, male WT mice had higher trabecular BMD
(+76.2%, p,0.05) and cortical periosteal circumference (+17.7%,
p,0.05) than female WT mice. In contrast, no significant gender
difference for these two parameters was seen in Srd5a1
2/2 mice
(Fig. 3 and Fig. 4). Thus, the normal gender differences on
Figure 1. Tissue distribution of 5a-reductase type 1–3. Real-time PCR showing the relative mRNA levels of Srd5a1 (type 1), Srd5a2 (type 2), and
Srd5a3 (type 3) in epididymis (Ep), prostate (Pr), liver (Li), bone (Bo) and heart (He). Values are given as % of levels in epididymis and are means 6 SEM
(males n=5, females n=5).
doi:10.1371/journal.pone.0021402.g001
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lost in Srd5a1
2/2 mice.
Neither the trabecular BMD nor the cortical BMC were
affected in one-month-old pre-pubertal Srd5a1
2/2 mice compared
with WT mice (data not shown).
Elevated androgen levels in female Srd5a1
2/2 mice
Serum levels of androgens and estradiol were not affected in
male Srd5a1
2/2 mice while both serum levels of T and DHT were
increased in adult female Srd5a1
2/2 mice compared with WT
mice (Table 3). To investigate if the increase in serum androgens
in female Srd5a1
2/2 was due to a disturbed central negative feed-
back regulation, serum levels of luteinizing hormone (LH) were
analyzed. Serum LH levels were not increased but rather
decreased in female Srd5a1
2/2 compared with WT mice,
suggesting a normal central negative feed-back regulation of
serum sex steroids in female Srd5a1
2/2 mice (Table 3). To address
the possibility that the high serum androgens could be the result of
a local disturbance in the ovaries associated with elevated
androgen synthesis, the ovarian morphology and LH receptor
(LHR) mRNA levels were analyzed. The ovaries in Srd5a1
2/2
mice had a normal morphology (Fig. 5), and the LHR mRNA
levels were unaffected (WT 1.060.3 and Srd5a1
2/2 1.160.2
LHR/GAPDH ratio; non-significant). Female Srd5a1
2/2 mice
had unchanged serum estradiol levels (Table 3) and displayed a
normal estrus cycle, with unaffected cycle length (WT 4.260.2
days, Srd5a1
2/2 4.360.3 days; non-significant).
To evaluate if the partial feminization of the male skeleton was
due to alterations in serum insulin like growth factor 1 (IGF-I)
and/or the growth hormone (GH)-secretion pattern, serum levels
of IGF-1 as well as major urinary protein (MUP; high levels
reflecting a male GH-secretion pattern; [32]) and prolactin
receptor (high levels reflecting a female GH-secretion pattern)
mRNA levels in the liver were measured. As expected, WT males
had higher MUP and lower prolactin receptor mRNA levels in the
liver compared to female mice. However, serum IGF-I, MUP
mRNA and prolactin receptor mRNA levels were not affected in
Srd5a1
2/2 mice compared with WT mice (Table 3).
Table 1. Body and organ weights.
Male Female
WT (n=7) KO (n=8) WT (n=13) KO (n=8)
Body weight (g) 34.260.8 31.661.4 25.660.6 26.961.9
Crown-rump length (mm) 60.560.4 59.460.5 56.860.6 57.361.0
Tibia length (mm) 19.060.2 18.860.2 18.460.2 18.560.2
Seminal vesicle weight/BW (mg/g) 7.960.4 8.160.8 NA NA
Uterus weight/BW (mg/g) NA NA 5.660.5 4.260.4
Gonadal fat weight/BW (mg/g) 33.662.8 32.563.3 51.963.1 45.565.1
Thymus weight/BW (mg/g) 1.660.1 1.560.1 2.560.2 2.060.1*
Liver weight/BW (mg/g) 35.261.7 36.261.3 35.861.5 37.161.5
M. tibialis weight/BW (mg/g) 1.3160.07 1.2260.07 1.1560.04 1.1860.06
M. quadriceps weight/BW (mg/g) 6.1960.25 5.9560.37 5.5660.20 5.4560.34
Four-month-old Srd5a1
2/2 (KO) and wild type (WT) mice. Values are means 6 SEM.
*p,0.05 Student’s t-test versus WT, NA=not applicable, BW=body weight, M=Muscle.
doi:10.1371/journal.pone.0021402.t001
Figure 2. Reduced areal BMD and BMC in male Srd5a1
2/2 mice. Areal bone mineral density (BMD; A) and bone mineral content (BMC; B) of
tibia as analyzed by DXA in four-month-old Srd5a1
2/2 (KO; males n=8, females n=8) and wild type (WT; males n=7, females n=13) mice. Values are
given as means 6 SEM. * p,0.05 Student’s t-test versus WT.
doi:10.1371/journal.pone.0021402.g002
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parameters in orchidectomized Srd5a1
2/2 mice
To determine if the responses to T treatment were affected by
5a-reductase inactivation, orchidectomized (orx) Srd5a1
2/2 mice
and orx WT mice were treated with T or placebo for four weeks.
As expected, weights of seminal vesicles and prostate, trabecular
BMD, cortical BMC and cortical periosteal circumference were
increased, while the weight of thymus was decreased by T
treatment in orx WT mice (Table 4). The significant effects of T
on prostate weight, trabecular BMD and thymus weight were
similar in orx Srd5a1
2/2 mice compared with orx WT. In
contrast, no significant effect of T was seen on the cortical bone
parameters in orx Srd5a1
2/2 mice (Table 4, Fig. 6).
Reduced forelimb muscle grip strength in Srd5a1
2/2
mice
The weights of the tibialis and quadriceps muscles were not
significantly affected in Srd5a1
2/2 mice compared with WT mice
(Table 1). Interestingly, male Srd5a1
2/2 mice had reduced
forelimb muscle strength compared with WT mice (Fig. 7). In
addition, T treated but not placebo treated orx Srd5a1
2/2 mice
had reduced forelimb muscle grip strength compared with
corresponding WT mice (Fig. 7). Thus, in the presence of either
endogenous or exogenous T, but not in the T deficient state, male
Srd5a1
2/2 mice demonstrated a reduced grip strength.
Discussion
Androgens are important regulators of bone mass, but the
relative importance of T versus DHT for the activation of the AR in
bone is unknown. Using Srd5a1
2/2 mice, we herein provide
evidence that 5a-reductase type 1 mediated conversion of T to
DHT in the target tissue results in a signal amplification of the
androgenic activity on bone mass and muscle strength without
affecting circulating androgen levels in male mice. In contrast, in
female mice 5a-reductase type 1 is mainly involved in the
degradation of androgens, supported by elevated circulating
androgen levels in female Srd5a1
2/2 mice.
The main finding of the present study was that male Srd5a1
2/2
mice had reduced bone mass although their circulating androgen
levels were unaffected. DXA analysis demonstrated that male
Srd5a1
2/2 mice had reduced areal BMD and further pQCT
analysis revealed that it was caused by a combination of reduced
trabecular BMD and cortical bone size compared with WT mice.
Figure 3. Reduced trabecular BMD in male Srd5a1
2/2 mice.
Trabecular bone mineral density (BMD) as analyzed by pQCT in the
distal metaphyseal region of femur in four-month-old Srd5a1
2/2 (KO;
males n=8, females n=8) and wild type (WT; males n=7, females
n=12) mice. Values are given as means 6 SEM. * p,0.05 Student’s
t-test versus WT.
doi:10.1371/journal.pone.0021402.g003
Figure 4. Cortical bone parameters in Srd5a1
2/2 mice. Cortical bone mineral content (BMC; A), area (B) and periosteal circumference (PC; C) as
analyzed by pQCT in the mid diaphyseal region of femur in four-month-old Srd5a1
2/2 (KO; males n=8, females n=8) and wild type (WT; males n=7,
females n=12) mice. Values are given as means 6 SEM. * p,0.05 Student’s t-test versus WT.
doi:10.1371/journal.pone.0021402.g004
Table 2. Cortical bone parameters.
Male Female
WT (n=7) KO (n=8) WT (n=12) KO (n=8)
Cortical vBMD (mg/cm
3) 127868 126669 125365 126868
Cortical thickness (mm) 25269 24366 20462 22463*
Endosteal circumference
(mm)
3.8860.13 3.4060.1* 3.3660.05 3.2260.05
MR (mm
3) 0.6560.04 0.5060.04* 0.3960.01 0.4260.02
MI (mm
4) 0.6860.06 0.4660.05* 0.3260.01 0.3360.02
Cortical bone parameter as analyzed by pQCT in the mid diaphyseal region of
femur in four-month-old Srd5a1
2/2 (KO) and wild type (WT) mice.
vBMD=volumetric bone mineral density, MR=cortical cross sectional moment
of resistance, MI=cortical cross sectional moment of inertia. Values are means
6 SEM.
*p,0.05 Student’s t-test versus WT.
doi:10.1371/journal.pone.0021402.t002
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deficient male mice [2] suggesting that it was caused by a lack of a
local 5a-reductase type 1 dependent amplification of the
androgenic signaling by conversion of T to the more potent
androgen DHT locally in bone. It is a limitation with the present
study that we did not treat the Srd5a1
2/2 mice with DHT as it
would have been a definitive proof that these KO mice can
respond to DHT and it might have provided some insight on the
relative importance of circulating vs. locally produced DHT. A
specific role of 5a-reductase type 1 in bone is supported by our
finding that the response to T treatment in orx Srd5a1
2/2 mice
was reduced in cortical bone but not in some other T responsive
tissues.
The normal gender difference with larger outer dimensions of
the cortical bone in males versus females was lost in the Srd5a1
2/2
mice. The sexual dimorphism of the skeleton has been linked to
gender differences in the GH-secretion pattern [32] but param-
eters reflecting gender specific GH-secretion were not affected in
the Srd5a1
2/2 mice compared with WT mice, supporting the
notion that the skeletal phenotype in male Srd5a1
2/2 mice was
due to lack of 5a-reductase type 1 expression in bone.
A role of 5a-reductase type 1 in bone is supported by previous
studies showing that 5a-reductase activity is present in human
bone [29] and 5a-reductase type 1 is expressed in cultured
osteoblasts [28]. In addition, in the present study we demonstrated
that 5a-reductase type 1 is clearly expressed while 5a-reductase
type 2 is barely expressed in mouse bone. Our findings suggest that
for optimal bone health it is beneficial to use 5a-reductase type 2
specific inhibitors (such as finasteride) and not combined type 2
and type 1 inhibitors in the treatment of patients with benign
prostatic hyperplasia and/or androgenetic alopecia.
Both muscle mass and strength have been associated with bone
mass and androgens are important regulators of both muscle mass
and strength [13,33]. Muscle mass was not significantly affected in
Srd5a1
2/2 mice, but interestingly, male Srd5a1
2/2 mice had
reduced forelimb muscle strength, suggesting that local 5a-
reductase type 1 expression is of importance for the signal
amplification of the androgenic activity not only in bone but also
in muscle. As exogenous testosterone treatment has been shown to
increase both muscle mass and muscle strength it is somewhat
unexpected that grip strength but not muscle mass was
significantly reduced in the male Srd5a1
2/2 mice [34]. However,
one cannot exclude that the lack of significant effect on muscle
mass was due to the relatively small number of mice evaluated.
Our findings may suggest that 5a-reductase type 1 specific
Figure 5. Ovarian morphology of WT and Srd5a1
2/2 (KO) mice. Hematoxylin and eosin stained ovarian sections from WT and KO mice. Bar
scale: 500 mm.
doi:10.1371/journal.pone.0021402.g005
Table 3. Serum levels of hormones and mRNA levels of major
urinary protein and prolactin receptor in liver.
Male Female
WT (n=7) KO (n=8) WT (n=13) KO (n=8)
Estradiol (pg/ml) 8.561.0 9.661.2 14.561.1 13.861.2
Testosterone (ng/ml) 6.761.2 6.561.1 ND 0.4360.24*
DHT (ng/ml) 1.5960.33 1.4860.28 0.1460.02 0.4160.10*
LH (ng/ml) NA NA 0.2560.05 0.1160.03*
IGF-1 (ng/ml) 200612 220614 174613 188619
Mup/GAPDH ratio 2.3060.48 2.2160.49 0.1260.02 0.1660.06
Prlr/GAPDH ratio 0.7160.21 0.4960.15 2.0660.24 2.4460.51
Serum hormone levels and relative amounts of liver major urinary protein (mup)
and prolactin receptor (Prlr) mRNA were measured in four-month-old Srd5a1
2/2
(KO) and wild type (WT) mice. Values are given as means 6 SEM.
*p,0.05 vs. wild-type (WT), NA=not available, ND=not detectable,
DHT=dihydrotestosterone, LH=luteinizing hormone, IGF-I=insulin like growth
factor 1.
doi:10.1371/journal.pone.0021402.t003
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osteoporosis and/or sarcopenia.
The total body weight and the weights of several visceral organs,
includingandrogensensitiveorganssuchasseminalvesiclesandthymus
werenormalinmaleSrd5a1
2/2mice,indicatingthattheeffectsseenon
bone mass and muscle strength are tissue-specific in males.
The phenotype of the female Srd5a1
2/2 mice is clearly
confounded by the elevated circulating levels of androgens, which
most probably caused the increased cortical bone mass and
reduced thymus weight. These two effects are well-established to
be caused by supra-physiological androgen treatment
[11,12,35,36]. Not only serum T but also serum DHT levels
were elevated in the female Srd5a1
2/2 mice, demonstrating that
5a-reductase type 1 is not crucial for the conversion of T to DHT
in female mice. The elevated serum androgen levels were not the
result of a disturbed negative feed-back regulation, supported by
the finding that serum LH was not elevated in female Srd5a1
2/2
mice. Female Srd5a1
2/2 mice displayed a normal ovarian
morphology and LH receptor mRNA levels and a normal estrus
cycle, with unaffected cycle length, indicating that there was no
major ovarian dysfunction leading to increased ovarian T
production. The high expression of 5a-reductase type 1 in liver
in WT mice together with the elevation of circulating androgen
levels in female Srd5a1
2/2 mice suggest that the elevated serum
androgen levels were a result of the lack of 5a-reductase type 1
dependent inactivation/degradation of androgens in the liver of
female Srd5a1
2/2 mice. An important role of 5a-reductase type 1
for androgen degradation in females is supported by several
previous studies [27,31,37,38]. No elevation of serum androgen
levels was seen in male Srd5a1
2/2 mice which could be explained
by the high expression of 5a-reductase type 2, normally seen in
male reproductive tissues, having the capacity to replace the 5a-
reductase type 1 enzyme in androgen degradation in male
Srd5a1
2/2 mice.
Since the female Srd5a1
2/2 mice had both increased circulating
levels of androgens and a deletion of Srd5a1
2/2, the physiological
role of Srd5a1
2/2 expression in bone cannot be evaluated by using
the female Srd5a1
2/2 mouse model. However, the female
Srd5a1
2/2 mouse model could be useful for studies evaluating
the role of chronic elevation of circulating androgen levels on for
Figure 6. Tissue dependent testosterone response in orchidectomized Srd5a1
2/2 mice. Four-month-old orchidectomized mice were either
treated with placebo or testosterone (1.5 mg/60days) for four weeks. The bars represent the testosterone response in percent for the Srd5a1
2/2 mice
compared to the testosterone response in WT mice. Thus, 0% means no testosterone response while 100% is a normal WT testosterone response (WT
orx n=12, WT orx+T n=10, KO orx n=8, KO orx+T n=8). Values are given as means 6 SEM. Weights of seminal vesicle (SV), prostate and thymus
were adjusted for body weight. BMC=bone mineral content, BMD=bone mineral density, PC=periosteal circumference, MR=cortical cross sectional
moment of resistance, MI=cortical cross sectional moment of inertia. Values are given as means 6 SEM.
doi:10.1371/journal.pone.0021402.g006
Table 4. Effect of T treatment in orchidectomized mice.
WT
(% over orx placebo)
KO
(%overorxplacebo)
Seminal vesicles weight/BW 1028658* 14136111*
Prostate weight/BW 390629* 430637*
Thymus weight/BW 26264* 27364*
Trabecular BMD 110616* 136629*
Cortical BMC 1663* 1264
Cortical area 1362* 1064
Cortical PC 4.961,4* 1.561,7
Cortical EC 2.861,8 23.062,3
Cortical MR 2765* 1266
Cortical MI 2967* 1267
Four-month-old orchidectomized (orx) mice were either treated with placebo or
testosterone (1.5 mg/60days) for four weeks. The effect of testosterone is given
as the testosterone treated group expressed as percent over the placebo
treated group in Srd5a1
2/2 (KO) and wild type (WT) mice (WT orx n=12, WT
orx+T n=10, KO orx n=8, KO orx+T n=8). Values are means 6 SEM. BW=body
weight, BMC=bone mineral content, BMD=bone mineral density,
PC=periosteal circumference, EC=endosteal circumference, MR=cross
sectional moment of resistance, MI=cross sectional moment of inertia.
*p,0.05 testosterone treated versus orx placebo.
doi:10.1371/journal.pone.0021402.t004
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genetic variants in the Srd5a1 gene have been associated with
two androgen linked conditions, polycystic ovary syndrome and
hirsutism, in females [38].
In conclusion, 5a-reductase type 1 inactivated male mice have
reduced bone mass and forelimb muscle grip strength and we
propose that these effects might be direct due to lack of 5a-
reductase type 1 expression in bone and muscle. In contrast, the
increased cortical bone mass in female Srd5a1
2/2 mice is an
indirect effect caused by elevated circulating androgen levels,
which in turn probably is a consequence of 5a-reductase type
1 expression being rate-limiting for androgen degradation in
female mice.
Materials and Methods
Animals
Animal care was in accordance with institutional guidelines and
the study protocol was approved by the local ethical committee
(permit number 362-2005 and 182-2006). All efforts were made to
minimize suffering. The mice were housed in a standard animal
facility under controlled temperature (22uC) and photoperiod
(12 h of light, 12 h of dark) with free access to water and standard
food. Srd5a1
2/2 mice were developed as previously described
[27]. Srd5a1
2/2 and littermate WT mice were analyzed at 1 (pre-
pubertal) and 4 (adult) months of age. In addition, four-month-old
orchidectomized (orx) Srd5a1
2/2 and WT mice were either
treated with placebo or T (1.5 mg/60days) for four weeks using
slow release pellets (Innovative Research of America, Sarasota, FL,
USA), delivering a physiological dose of T or placebo. Initial
detailed dose-response studies of the effect of T established a dose
of 1.5 mg/60 days to normalize the weight of the seminal vesicles
in orx WT mice.
Dual X-ray absorption analysis
Areal bone mineral density and bone mineral content of excised
tibia were measured by DXA using the Lunar PIXImus Mouse
Densitometer (Wipro GE Healthcare, Madison, WI).
Peripheral Quantitative Computerized Tomography
analyses
Computerized tomography was performed with the STRATEC
pQCT XCT, operating at a resolution of 70 mm as previously
described [14]. Trabecular BMD was determined ex vivo, with a
metaphyseal pQCT scan of the distal femur. The scan was
positioned in the metaphysis at a distance from the distal growth
plate corresponding to 4% of the total length of the femur, and the
trabecular bone region was defined as the inner 45% of the total
cross-sectional area. Cortical bone parameters were determined ex
vivo with a mid-diaphyseal pQCT scan of the long bones [39].
Serum analyses
Serum analyses were performed according to the manufactur-
er’s instructions for estradiol (Estradiol ELISA, Bioquant, San
Diego, CA, sensitivity 5 pg/ml, intra-assay variation 10.3%), T
(RIA, MP Biomedicals /ICN Biomedicals, Costa Mesa, CA,
sensitivity 0.1 ng/ml, intra-assay variation 9.1%), DHT (ELISA
kit from Alpha diagnostic International, San Antonio, TX,
sensitivity 25 pg/ml, intra-assay variation 10.5%), luteinizing
hormone (RIA AHR002, IDS Biocode-Hycel, Liege, Belgium,
sensitivity 0.14 ng/ml, intra-assay variation 10.5%) and insulin
like growth factor-1 (RIA, Mediagnost, Reutingen, Germany,
sensitivity 0,020 ng/ml, intra-assay variation ,3%).
Ovarian analyses and vaginal smears
Ovaries were fixed in a 4% formaldehyde neutral-buffered
solution for 24 h at 4uC and embedded in paraffin and sectioned
in 5 mm sections for histological analyses. Ovarian sections were
deparaffinised, rehydrated and stained with hematoxylin and
eosin. The stage of cyclicity was determined by microscopic
analysis of the predominant cell type in vaginal smears obtained
daily during two cycles [40]. The vaginal smears were stained with
hematoxylin and eosin using standard protocols and staged by
light microscopy. Care was taken to avoid mechanical stimulation
of the cervix during this procedure to prevent pseudopregnancy.
Real-time PCR
RNA was prepared from liver, heart, prostate and epididymis
using RNeasy kit (#74106, Qiagen, Hilden, Germany) according
to the manufacturer’s instructions. Total RNA from humerus was
prepared using TriZol Reagent (Invitrogen, Lidingo ¨, Sweden).
The RNA was reverse transcribed into cDNA using High-capacity
cDNA Reverse transcription kit (#4368814, Applied Biosystems,
Stockholm, Sweden). Real-time PCR (RT-PCR) analyses were
performed using the ABI Prism 7000 Sequence Detection System
(PE Applied Biosystems, Carlsbad, CA). We used pre-designed
RT-PCR assays from Applied Biosystems for the analysis of
Srd5a1 (Mm00614213_ml), Srd5a2 (Mm01237407_ml), Srd5a3
(Mm00491099_m1), prolactin receptor (Mm00599957_m1), LH
receptor (Mm00442931_m1) and GAPDH (internal control,
4352339E) mRNA levels (Applied Biosystems). For analysis of
major urinary protein (MUP), the following forward primer MUP-
1FP 59GCT GCT GTG TTT GGG ACT GA, reverse primer
MUP-1RP 59AAG TTC CTT CCC GTA GAA CTA GCTT and
probe MUP-1 MGB-Probe 59CCT AGT CTG TGT CCA
TGCA were used.
Forelimb muscle grip strength
The forelimb muscle grip strength was determined using an
automated grip strength meter (Columbus Instruments, Colum-
bus, OH). Mice were lifted by their tail and were made to hold a
horizontal bar with their forelimbs. Then, the mice were pulled
Figure 7. Reduced forelimb grip strength in male Srd5a1
2/2
mice. Grip strength in four-month-old gonadal intact (sham-operated)
Srd5a1
2/2 (KO; n=18) and wild type (WT; n=27) mice. In addition, four-
month-old orchidectomized (orx) KO and WT mice were either treated
with placebo (Orx) or testosterone (Orx+T) for four weeks (WT orx
n=13, WT orx+T n=13, KO orx n=8, KO orx+T n=8). Values are means
6 SEM. * p,0.05 Student’s t-test versus WT.
doi:10.1371/journal.pone.0021402.g007
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was registered during consecutive attempts (four attempts/mouse
for sham mice and eight attempts/mouse for orx mice) and the
result was set as the average of the four best attempts. The analysis
was performed in a blinded fashion.
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